Published in Clin Infect Dis on August 01, 2012
Fidaxomicin inhibits spore production in Clostridium difficile. Clin Infect Dis (2012) 1.15
Both fidaxomicin and vancomycin inhibit outgrowth of Clostridium difficile spores. Antimicrob Agents Chemother (2012) 0.92
Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection. Can J Infect Dis Med Microbiol (2016) 0.82
Fidaxomicin inhibits Clostridium difficile toxin A-mediated enteritis in the mouse ileum. Antimicrob Agents Chemother (2014) 0.80
Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review. Curr Top Med Chem (2014) 0.79
Comparative microbiological studies of transcription inhibitors fidaxomicin and the rifamycins in Clostridium difficile. Antimicrob Agents Chemother (2014) 0.79
Bacterial RNA Polymerase-DNA Interaction-The Driving Force of Gene Expression and the Target for Drug Action. Front Mol Biosci (2016) 0.77
Bacterial Transcription as a Target for Antibacterial Drug Development. Microbiol Mol Biol Rev (2016) 0.77
rRNA (rrn) operon-engineered Bacillus subtilis as a feasible test organism for antibiotic discovery. Antimicrob Agents Chemother (2013) 0.76
Treatment of Clostridium difficile infection: recent trial results. Clin Investig (Lond) (2013) 0.75
Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes. Can J Infect Dis Med Microbiol (2016) 0.75
Fidaxomicin--the new drug for Clostridium difficile infection. Indian J Med Res (2015) 0.75
A new method for the large scale purification of Escherichia coli deoxyribonucleic acid-dependent ribonucleic acid polymerase. J Biol Chem (1969) 12.49
Structural mechanism for rifampicin inhibition of bacterial rna polymerase. Cell (2001) 6.10
Crystal structure of Thermus aquaticus core RNA polymerase at 3.3 A resolution. Cell (1999) 5.88
Inhibition of bacterial RNA polymerase by streptolydigin: stabilization of a straight-bridge-helix active-center conformation. Cell (2005) 2.88
Allosteric control of Escherichia coli rRNA promoter complexes by DksA. Genes Dev (2009) 2.59
Mechanism of bacterial transcription initiation: RNA polymerase - promoter binding, isomerization to initiation-competent open complexes, and initiation of RNA synthesis. J Mol Biol (2011) 2.50
Structural basis of transcription inhibition by antibiotic streptolydigin. Mol Cell (2005) 2.40
The RNA polymerase "switch region" is a target for inhibitors. Cell (2008) 1.96
Antibacterial peptide microcin J25 inhibits transcription by binding within and obstructing the RNA polymerase secondary channel. Mol Cell (2004) 1.80
Structural, functional, and genetic analysis of sorangicin inhibition of bacterial RNA polymerase. EMBO J (2005) 1.71
Structural basis for transcription inhibition by tagetitoxin. Nat Struct Mol Biol (2005) 1.64
A new class of bacterial RNA polymerase inhibitor affects nucleotide addition. Science (2003) 1.63
Transcription inactivation through local refolding of the RNA polymerase structure. Nature (2008) 1.63
Allosteric modulation of the RNA polymerase catalytic reaction is an essential component of transcription control by rifamycins. Cell (2005) 1.52
Molecular mechanism of transcription inhibition by peptide antibiotic Microcin J25. Mol Cell (2004) 1.49
Molecular evolution of multisubunit RNA polymerases: structural analysis. J Mol Biol (2009) 1.45
Lipiarmycin, a new antibiotic from Actinoplanes III. Mechanism of action. J Antibiot (Tokyo) (1975) 1.43
Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis. J Antimicrob Chemother (2008) 1.28
Lipiarmycin: an antibiotic inhibiting nucleic acid polymerases. Biochem Biophys Res Commun (1975) 1.24
Chemical modifications and biological properties of rifamycins. Antimicrob Agents Chemother (Bethesda) (1966) 1.17
Initiation of transcription in vitro inhibited by lipiarmycin. J Mol Biol (1979) 1.17
Lipiarmycin, a new antibiotic from Actinoplanes. I. Description of the producer strain and fermentation studies. J Antibiot (Tokyo) (1975) 1.14
The transcription inhibitor lipiarmycin blocks DNA fitting into the RNA polymerase catalytic site. EMBO J (2010) 1.02
Purification and characterization of the DNA-dependent RNA polymerase from Clostridium acetobutylicum. J Bacteriol (1991) 0.86
Structure and biological activity of lipiarmycin B. J Antibiot (Tokyo) (1988) 0.84
Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med (2011) 10.29
Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis (2012) 3.71
Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection. Antimicrob Agents Chemother (2011) 1.33
Fidaxomicin inhibits spore production in Clostridium difficile. Clin Infect Dis (2012) 1.15
Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. J Med Microbiol (2011) 1.10
A three-fluorophore FRET assay for high-throughput screening of small-molecule inhibitors of ribosome assembly. Nucleic Acids Res (2004) 1.09
Whole-genome sequencing demonstrates that fidaxomicin is superior to vancomycin for preventing reinfection and relapse of infection with Clostridium difficile. J Infect Dis (2013) 1.04
Fidaxomicin inhibits toxin production in Clostridium difficile. J Antimicrob Chemother (2012) 1.01
Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. Antimicrob Agents Chemother (2011) 0.94
Saccharide display on microtiter plates. Chem Biol (2002) 0.93
Synthesis and high-throughput screening of N-acetyl-beta-hexosaminidase inhibitor libraries targeting osteoarthritis. J Org Chem (2004) 0.92
Comparative microbiological studies of transcription inhibitors fidaxomicin and the rifamycins in Clostridium difficile. Antimicrob Agents Chemother (2014) 0.79
Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. Bioorg Med Chem Lett (2005) 0.77
Synthesis and biological activity of new 5-O-sugar modified ketolide and 2-fluoro-ketolide antibiotics. Bioorg Med Chem Lett (2005) 0.75
Glyco-optimization of aminoglycosides: new aminoglycosides as novel anti-infective agents. Bioorg Med Chem Lett (2004) 0.75